Overall, our results suggested that hypo-DNA methylation, DNA amplification, and TP53 mutation were combined contributing to the high expression levels of pyrimidine metabolic rate–limiting enzymes in lung cancer cells. This evidence concerns the gene TP53 and lung carcinoma.